{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:37Z","timestamp":1791347317300,"version":"4.3.1"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal dose of efavirenz for HIV-infected patients receiving a tuberculosis regimen including rifampicin remains debated, especially for subjects weighing over 50 kg. To address this issue, we measured plasma efavirenz concentrations from Cambodian adults with tuberculosis enrolled in the CAMELIA randomized trial (ClinicalTrials.gov number, NCT01300481) 6 weeks after the onset of antiretroviral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Efavirenz concentrations and proportions of patients with concentrations below 1,000 ng\/ml were compared across patient body weight below or above 50 kg using a Student's t-test and a c\n                      <jats:sup>2<\/jats:sup>\n                      test, respectively. Factors associated with efavirenz concentrations below 1,000 ng\/ml were identified by logistic regression analysis. Logistic regression analysis was also performed to check if efavirenz concentrations below 1,000 ng\/ml were associated with virological failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma efavirenz concentrations were higher in the 332 patients who weighed &lt;50 kg compared with the 150 who weighed \u226550 kg (median [IQR] 2,859 [1,787\u20134,749] and 2,060 [1,425\u20133,575] ng\/ml, respectively; P=0.02). However, the proportion of patients with efavirenz concentrations below 1,000 ng\/ml was not different between those weighing less than or more than 50 kg (6% and 10%, respectively; P=0.13) and a body weight above 50 kg was not associated with a higher risk of plasma efavirenz concentrations below 1,000 ng\/ml. When plasma efavirenz concentrations below 1,000 ng\/ml were present, they were not associated with virological failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current WHO guidelines recommending 600 mg efavirenz daily irrespective of patient's body weight remains a safe and effective approach to treating coinfected adults needing simultaneous tuberculosis and HIV therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp2483","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T10:39:01Z","timestamp":1355308741000},"page":"419-423","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Plasma Concentrations of Efavirenz with a 600 Mg Standard Dose in Cambodian HIV-Infected Adults Treated for Tuberculosis with a Body Weight above 50 Kg"],"prefix":"10.1177","volume":"18","author":[{"given":"Laurence","family":"Borand","sequence":"first","affiliation":[{"name":"Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Laureillard","sequence":"additional","affiliation":[{"name":"ANRS, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoann","family":"Madec","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche et d'Expertise Epid\u00e9miologie des Maladies Emergentes, Institut Pasteur, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monidarin","family":"Chou","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Health Sciences, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phearavin","family":"Pheng","sequence":"additional","affiliation":[{"name":"Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Marcy","sequence":"additional","affiliation":[{"name":"Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thim","family":"Sok","sequence":"additional","affiliation":[{"name":"Cambodian Health Committee, Phnom Penh, Cambodia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E","family":"Goldfeld","sequence":"additional","affiliation":[{"name":"Cambodian Health Committee, Phnom Penh, Cambodia"},{"name":"Immune Disease Institute, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Taburet","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, H\u00f4pitaux Universitaires Paris Sud, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Blanc","sequence":"additional","affiliation":[{"name":"Pneumology Department, Assistance Publique - H\u00f4pitaux de Paris, H\u00f4pital Bic\u00eatre, H\u00f4pitaux Universitaires Paris Sud, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the CAMELIA (ANRS 1295-CIPRA KH001) study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,4,1]]},"reference":[{"key":"bibr1-IMP2483","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1166-5"},{"key":"bibr2-IMP2483","unstructured":"World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 Revision. (Accessed 15 August 2012.) Available from http:\/\/whqlibdoc.who.int\/publications\/2010\/9789241599764_eng.pdf."},{"key":"bibr3-IMP2483","unstructured":"US Food and Drug Administration. Sustiva labeling update\/ dosing adjustment with rifampin. (Updated 3 February 2012. Accessed 15 August 2012.) Available from http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm294476.htm."},{"key":"bibr4-IMP2483","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7961"},{"key":"bibr5-IMP2483","unstructured":"British HIV Association. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. (Updated 30 April 2012. Accessed 15 August 2012.) Available from http:\/\/www.bhiva.org\/documents\/Guidelines\/Treatment\/2012\/120430TreatmentGuidelines.pdf."},{"key":"bibr6-IMP2483","unstructured":"Yeni P. Management of people living with HIV\/AIDS: recommendations from the French expert panel. French. (Updated 19 July 2010. Accessed 15 August 2012.) Available from http:\/\/www.sante.gouv.fr\/IMG\/pdf\/Rapport_2010_sur_la_prise_en_charge_medicale_des_personnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni.pdf."},{"key":"bibr7-IMP2483","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013911"},{"key":"bibr8-IMP2483","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200101050-00011"},{"key":"bibr9-IMP2483","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183630.27665.30"},{"key":"bibr10-IMP2483","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","volume":"14","author":"Cohen K.","year":"2009","journal-title":"Antivir Ther"},{"key":"bibr11-IMP2483","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1780"},{"key":"bibr12-IMP2483","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl399"},{"key":"bibr13-IMP2483","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03883.x"},{"key":"bibr14-IMP2483","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241090-00004"},{"key":"bibr15-IMP2483","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl357"},{"key":"bibr16-IMP2483","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000196181.18916.9b"},{"key":"bibr17-IMP2483","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000183519.45137.a6"},{"key":"bibr18-IMP2483","first-page":"2391","volume":"18","author":"Haas D.W.","year":"2004","journal-title":"AIDS"},{"key":"bibr19-IMP2483","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00512-10"},{"key":"bibr20-IMP2483","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05452-11"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2483","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP2483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:51:18Z","timestamp":1777380678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP2483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.3851\/IMP2483"],"URL":"https:\/\/doi.org\/10.3851\/imp2483","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}